Skip to main content
. 2020 Aug 12;11:2039. doi: 10.3389/fimmu.2020.02039

FIGURE 6.

FIGURE 6

(A) Possible mechanism underlying the difference in the efficacy of ICI treatment in CRC patients with different MSI statuses. (B) The high expression of immune checkpoints in the GEP of MSI-H CRC indicates targets for ICIs.